AACR

Fewer actionable mutations, less likely to meet genomic criteria for immunotherapy

ORR of 30% in patients with CD70-positive disease using off-the-shelf, allogeneic product

Moreover, a significant proportion do not qualify for genetic screening under current guidelines

All but one patient had a PSA decline after a fractionated dose of 225Ac-J591

Overall response rate of 90% in patients who received highest doses of REGN5459

Responses in 37% of patients previously treated with anti-PD-1/L1 agents, platinum chemotherapy

"One of the highest tumor response rates we've seen in any cancer," study discussant says

Another option for difficult-to-treat disease

Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival

Atezolizumab-bevacizumab reduced the risk of recurrence by about 30%

Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies

But response rate driven primarily by injected lesions, expert points out

Responses in a majority of patients, evidence of durability with TTX-030, chemoimmunotherapy

Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone